ArticlePloS one2015
Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 2 syntheses or guidelines pooled it, 172 citations in OpenAlex.
- Efficacy and safety of tACS in older adults with cognitive impairment: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Pooled it
- A Systematic Review of Practice Guidelines and Recommendations for Discontinuation of Cholinesterase Inhibitors in Dementia.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2018Pooled it
- Multi-Target Neuroprotective Effects of Cordycepin and Adenosine fromBiomedicines · 2026Article
- Hospitalization for Malignant Arrhythmias Following Initiation of Donepezil: A Retrospective Cohort Study.Pharmacoepidemiology and drug safety · 2026Article
- Comparative effects of some pharmacological and non-pharmacological interventions on cognitive function in Alzheimer's disease: A Bayesian network meta-analysis.The journal of prevention of Alzheimer's disease · 2026Article
- Brain morphological characteristics predicting clinical response to selective serotonin reuptake inhibitors or cholinesterase inhibitors: A study of electronic medical records in patients with cognitive disorders.International psychogeriatrics · 2025Observational
- Identifying high-risk drugs and demographic patterns in drug-induced liver injury from FAERS and CVARD analyses.Scientific reports · 2025Article
- Comparative safety of cholinesterase inhibitors and memantine for dementia: a protocol for a network meta-analysis of randomized controlled trials.Systematic reviews · 2025Article
- Evaluation of the toxicity of essential oil ofToxicology research · 2025Article
- Nebulized seabuckthorn seed oil inhalation attenuates Alzheimer's disease progression in APP/PS1 mice.Scientific reports · 2025Article
- Investigating the therapeutic effects of Shenzhiling oral liquid on Alzheimer's disease: a network pharmacology and experimental approach.3 Biotech · 2025Article
- Real-world safety profile of roflumilast: a pharmacovigilance analysis using FDA adverse event reporting system and Canada vigilance database.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2025Article
- Unveiling the hidden risk of caspofungin: insights from three adverse event reporting systems and network pharmacology integration.Frontiers in pharmacology · 2025Article
- Drug-induced dementia: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database.Therapeutic advances in neurological disorders · 2025Article
- Shen Zhi Ling oral liquid improve neuroinflammation against Alzheimer's disease via the PI3K/Akt pathway.3 Biotech · 2025Article
- Cholinesterase Inhibitor Initiation Does Not Increase the Risk of Fall-Related Injury in Older Adults Treated With Beta-Blockers: A Self-Controlled Case Series Design.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024Article
- Association between Polypharmacy and Adverse Events in Patients with Alzheimer's Disease: An Analysis of the Japanese Adverse Drug Event Report Database (JADER).Medicina (Kaunas, Lithuania) · 2024Article
- Development and validation of a clinical prediction model for osteonecrosis of the jaw in patients receiving zoledronic acid using FAERS and canadian databases.Frontiers in pharmacology · 2024Article
- Alzheimer's disease and its treatment-yesterday, today, and tomorrow.Frontiers in pharmacology · 2024Review
- Improper Application of a Rivastigmine Patch to the Back of the Neck Induced Toxic Symptoms.Internal medicine (Tokyo, Japan) · 2023Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
This survey analyzes two national pharmacovigilance databases in order to determine the major adverse reactions observed with the use of cholinesterase inhibitors in dementia. We conducted a statistical analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) and the Canada Vigilance Adverse Reaction Database (CVARD) concerning the side effects of cholinesterase inhibitors. The statistics calculated for each adverse event were the frequency and the reporting odds ratios (ROR). A total of 9877 and 2247 reports were extracted from the FAERS and CVARD databases, respectively. A disproportionately higher frequency of reports of death as an adverse event for rivastigmine, compared to the other acetylcholinesterase inhibiting drugs, was observed in both the FAERS (ROR = 3.42; CI95% = 2.94-3.98; P<0.0001) and CVARD (ROR = 3.67; CI95% = 1.92-7.00; P = 0.001) databases. While cholinesterase inhibitors remain to be an important therapeutic tool against Alzheimer's disease, the disproportionate prevalence of fatal outcomes with rivastigmine compared with alternatives should be taken into consideration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.